Klein Christian, Medina Eva, Sander Leif, Dierssen Uta, Roskams Tania, Mueller Werner, Trautwein Christian, Goldmann Oliver
Medizinische Klinik III, University Hospital Aachen, Rheinisch-Westfalisch Techniche Hochschule Aachen, Aachen, Germany.
J Infect Dis. 2007 Sep 1;196(5):755-62. doi: 10.1086/520090. Epub 2007 Jul 13.
Sepsis and septic shock caused by gram-positive bacteria have become increasingly frequent clinical problems. These conditions are accompanied by an overwhelming inflammation in which the liver plays a central role as a source and target of inflammatory mediators. Sepsis is still associated with high mortality rates, and new intervention strategies directed at ameliorating the extent of the inflammatory reaction are strongly needed. Here, we investigated whether blockage of the transducer gp130, a receptor involved in the regulation of the inflammatory response, might be useful in the treatment of experimental gram-positive sepsis.
An experimental model of gram-positive sepsis was used in which liver-specific gp130-deficient mice (FVB/n alfpCre+ gp130(LoxP/LoxP)) and wild-type mice (FVB/n gp130(LoxP/LoxP)) were intravenously infected with Streptococcus pyogenes. The following parameters were monitored: mortality, bacterial loads in systemic organs, serum inflammatory cytokine levels, and organ damage.
We show that infected gp130-deficient mice survived significantly longer, had lower bacterial loads, and developed organ damage more slowly than infected wild-type mice. Furthermore, levels of interferon- gamma , interleukin-6, and the chemokine cytokine-induced neutrophil chemoattractant were significantly lower in gp130-deficient mice than in wild-type mice. Histopathological examination of livers showed lower amounts of neutrophil infiltration, apoptosis, and tissue damage in infected gp130-deficient mice than in wild-type mice.
Our results demonstrate that the gp130 receptor is involved in the regulation of inflammation during gram-positive sepsis and that blockage of gp130 signaling in hepatocytes could constitute a novel target for adjunctive therapy in patients with sepsis.
革兰氏阳性菌引起的脓毒症和脓毒性休克已成为日益常见的临床问题。这些病症伴随着过度炎症反应,其中肝脏作为炎症介质的来源和靶点发挥着核心作用。脓毒症仍然与高死亡率相关,因此迫切需要新的干预策略来减轻炎症反应的程度。在此,我们研究了阻断转导蛋白gp130(一种参与炎症反应调节的受体)是否有助于治疗实验性革兰氏阳性菌脓毒症。
采用革兰氏阳性菌脓毒症实验模型,将肝脏特异性gp130缺陷小鼠(FVB/n alfpCre+ gp130(LoxP/LoxP))和野生型小鼠(FVB/n gp130(LoxP/LoxP))静脉注射化脓性链球菌。监测以下参数:死亡率、全身器官中的细菌载量、血清炎症细胞因子水平和器官损伤情况。
我们发现,与感染的野生型小鼠相比,感染的gp130缺陷小鼠存活时间显著延长,细菌载量更低,器官损伤发展更缓慢。此外,gp130缺陷小鼠体内的干扰素-γ、白细胞介素-6以及趋化因子细胞因子诱导的中性粒细胞趋化因子水平显著低于野生型小鼠。肝脏组织病理学检查显示,与野生型小鼠相比,感染的gp130缺陷小鼠肝脏中的中性粒细胞浸润、细胞凋亡和组织损伤程度更低。
我们的结果表明,gp130受体参与革兰氏阳性菌脓毒症期间的炎症调节,肝细胞中gp130信号的阻断可能成为脓毒症患者辅助治疗的新靶点。